{"id":6492,"date":"2020-12-14T13:02:00","date_gmt":"2020-12-14T13:02:00","guid":{"rendered":"https:\/\/www.adacyte.com\/?post_type=scientific-corner&p=6492"},"modified":"2024-05-02T11:30:55","modified_gmt":"2024-05-02T09:30:55","slug":"evidence-based-clinical-practice-guidelines-for-inflammatory-bowel-disease-2020","status":"publish","type":"scientific-corner","link":"https:\/\/www.adacyte.com\/es\/professional\/scientific-corner\/evidence-based-clinical-practice-guidelines-for-inflammatory-bowel-disease-2020\/","title":{"rendered":"Evidence-based clinical practice guidelines for inflammatory bowel disease 2020"},"content":{"rendered":"
\n

Hiroshi Nakase<\/a>,1,2<\/sup>Motoi Uchino<\/a>,1<\/sup>Shinichiro Shinzaki<\/a>,1<\/sup>Minoru Matsuura<\/a>,1<\/sup>Katsuyoshi Matsuoka<\/a>,1<\/sup>Taku Kobayashi<\/a>,1<\/sup>Masayuki Saruta<\/a>,1<\/sup>Fumihito Hirai<\/a>,1<\/sup>Keisuke Hata<\/a>,1<\/sup>Sakiko Hiraoka<\/a>,1<\/sup>Motohiro Esaki<\/a>,1<\/sup>Ken Sugimoto<\/a>,1<\/sup>Toshimitsu Fuji<\/a>,1<\/sup>Kenji Watanabe<\/a>,1<\/sup>Shiro Nakamura<\/a>,1<\/sup>Nagamu Inoue<\/a>,1<\/sup>Toshiyuki Itoh<\/a>,1<\/sup>Makoto Naganuma<\/a>,1<\/sup>Tadakazu Hisamatsu<\/a>,1<\/sup>Mamoru Watanabe<\/a>,1<\/sup>Hiroto Miwa<\/a>,1<\/sup>Nobuyuki Enomoto<\/a>,1<\/sup>Tooru Shimosegawa<\/a>,1<\/sup>\u00a0and\u00a0Kazuhiko Koike<\/a>1<\/sup> ,J Gastroenterol.<\/a>\u00a02021; 56(6): 489\u2013526.<\/p>\n<\/div>\n\n

\n

Inflammatory bowel disease (IBD) is a general term for chronic or remitting\/relapsing inflammatory diseases of the intestinal tract and generally refers to ulcerative colitis (UC) and Crohn\u2019s disease (CD). Since 1950, the number of patients with IBD in Japan has been increasing. The etiology of IBD remains unclear; however, recent research data indicate that the pathophysiology of IBD involves abnormalities in disease susceptibility genes, environmental factors and intestinal bacteria. The elucidation of the mechanism of IBD has facilitated therapeutic development. UC and CD display heterogeneity in inflammatory and symptomatic burden between patients and within individuals over time. Optimal management depends on the understanding and tailoring of evidence-based interventions by physicians. In 2020, seventeen IBD experts of the Japanese Society of Gastroenterology revised the previous guidelines for IBD management published in 2016. This English version was produced and modified based on the existing updated guidelines in Japanese. The Clinical Questions (CQs) of the previous guidelines were completely revised and categorized as follows: Background Questions (BQs), CQs, and Future Research Questions (FRQs). The guideline was composed of a total of 69 questions: 39 BQs, 15 CQs, and 15 FRQs. The overall quality of the evidence for each CQ was determined by assessing it with reference to the Grading of Recommendations Assessment, Development and Evaluation approach, and the strength of the recommendation was determined by the Delphi consensus process. Comprehensive up-to-date guidance for on-site physicians is provided regarding indications for proceeding with the diagnosis and treatment.<\/p>\n<\/div>\n\n

\n

https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8137635\/<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

Hiroshi Nakase,1,2Motoi Uchino,1Shinichiro Shinzaki,1Minoru Matsuura,1Katsuyoshi Matsuoka,1Taku Kobayashi,1Masayuki Saruta,1Fumihito Hirai,1Keisuke Hata,1Sakiko Hiraoka,1Motohiro Esaki,1Ken Sugimoto,1Toshimitsu Fuji,1Kenji Watanabe,1Shiro Nakamura,1Nagamu Inoue,1Toshiyuki Itoh,1Makoto Naganuma,1Tadakazu Hisamatsu,1Mamoru Watanabe,1Hiroto Miwa,1Nobuyuki Enomoto,1Tooru Shimosegawa,1\u00a0and\u00a0Kazuhiko Koike1 ,J Gastroenterol.\u00a02021; 56(6): 489\u2013526. Inflammatory bowel disease (IBD) is a general term for chronic or remitting\/relapsing inflammatory diseases of the intestinal tract and generally refers to ulcerative colitis (UC) and […]<\/p>\n","protected":false},"template":"","scientific_tags":[159,374,306],"class_list":["post-6492","scientific-corner","type-scientific-corner","status-publish","hentry","scientific_tags-crohns-disease","scientific_tags-inflammatory-bowel-disease","scientific_tags-ulcerative-colitis"],"acf":{"sc_authors":"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8137635\/<\/a>"},"yoast_head":"\nEvidence-based clinical practice guidelines for inflammatory bowel disease 2020 - Adacyte<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/evidence-based-clinical-practice-guidelines-for-inflammatory-bowel-disease-2020\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Evidence-based clinical practice guidelines for inflammatory bowel disease 2020 - Adacyte\" \/>\n<meta property=\"og:description\" content=\"Hiroshi Nakase,1,2Motoi Uchino,1Shinichiro Shinzaki,1Minoru Matsuura,1Katsuyoshi Matsuoka,1Taku Kobayashi,1Masayuki Saruta,1Fumihito Hirai,1Keisuke Hata,1Sakiko Hiraoka,1Motohiro Esaki,1Ken Sugimoto,1Toshimitsu Fuji,1Kenji Watanabe,1Shiro Nakamura,1Nagamu Inoue,1Toshiyuki Itoh,1Makoto Naganuma,1Tadakazu Hisamatsu,1Mamoru Watanabe,1Hiroto Miwa,1Nobuyuki Enomoto,1Tooru Shimosegawa,1\u00a0and\u00a0Kazuhiko Koike1 ,J Gastroenterol.\u00a02021; 56(6): 489\u2013526. Inflammatory bowel disease (IBD) is a general term for chronic or remitting\/relapsing inflammatory diseases of the intestinal tract and generally refers to ulcerative colitis (UC) and […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/evidence-based-clinical-practice-guidelines-for-inflammatory-bowel-disease-2020\/\" \/>\n<meta property=\"og:site_name\" content=\"Adacyte\" \/>\n<meta property=\"article:modified_time\" content=\"2024-05-02T09:30:55+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/evidence-based-clinical-practice-guidelines-for-inflammatory-bowel-disease-2020\/\",\"url\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/evidence-based-clinical-practice-guidelines-for-inflammatory-bowel-disease-2020\/\",\"name\":\"Evidence-based clinical practice guidelines for inflammatory bowel disease 2020 - Adacyte\",\"isPartOf\":{\"@id\":\"https:\/\/www.adacyte.com\/#website\"},\"datePublished\":\"2020-12-14T13:02:00+00:00\",\"dateModified\":\"2024-05-02T09:30:55+00:00\",\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/evidence-based-clinical-practice-guidelines-for-inflammatory-bowel-disease-2020\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.adacyte.com\/#website\",\"url\":\"https:\/\/www.adacyte.com\/\",\"name\":\"Adacyte\",\"description\":\"Adacyte Therapeutics\",\"publisher\":{\"@id\":\"https:\/\/www.adacyte.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.adacyte.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.adacyte.com\/#organization\",\"name\":\"Adacyte\",\"url\":\"https:\/\/www.adacyte.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"contentUrl\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"width\":165,\"height\":46,\"caption\":\"Adacyte\"},\"image\":{\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Evidence-based clinical practice guidelines for inflammatory bowel disease 2020 - Adacyte","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/evidence-based-clinical-practice-guidelines-for-inflammatory-bowel-disease-2020\/","og_locale":"es_ES","og_type":"article","og_title":"Evidence-based clinical practice guidelines for inflammatory bowel disease 2020 - Adacyte","og_description":"Hiroshi Nakase,1,2Motoi Uchino,1Shinichiro Shinzaki,1Minoru Matsuura,1Katsuyoshi Matsuoka,1Taku Kobayashi,1Masayuki Saruta,1Fumihito Hirai,1Keisuke Hata,1Sakiko Hiraoka,1Motohiro Esaki,1Ken Sugimoto,1Toshimitsu Fuji,1Kenji Watanabe,1Shiro Nakamura,1Nagamu Inoue,1Toshiyuki Itoh,1Makoto Naganuma,1Tadakazu Hisamatsu,1Mamoru Watanabe,1Hiroto Miwa,1Nobuyuki Enomoto,1Tooru Shimosegawa,1\u00a0and\u00a0Kazuhiko Koike1 ,J Gastroenterol.\u00a02021; 56(6): 489\u2013526. Inflammatory bowel disease (IBD) is a general term for chronic or remitting\/relapsing inflammatory diseases of the intestinal tract and generally refers to ulcerative colitis (UC) and […]","og_url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/evidence-based-clinical-practice-guidelines-for-inflammatory-bowel-disease-2020\/","og_site_name":"Adacyte","article_modified_time":"2024-05-02T09:30:55+00:00","twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/evidence-based-clinical-practice-guidelines-for-inflammatory-bowel-disease-2020\/","url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/evidence-based-clinical-practice-guidelines-for-inflammatory-bowel-disease-2020\/","name":"Evidence-based clinical practice guidelines for inflammatory bowel disease 2020 - Adacyte","isPartOf":{"@id":"https:\/\/www.adacyte.com\/#website"},"datePublished":"2020-12-14T13:02:00+00:00","dateModified":"2024-05-02T09:30:55+00:00","inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adacyte.com\/professional\/scientific-corner\/evidence-based-clinical-practice-guidelines-for-inflammatory-bowel-disease-2020\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.adacyte.com\/#website","url":"https:\/\/www.adacyte.com\/","name":"Adacyte","description":"Adacyte Therapeutics","publisher":{"@id":"https:\/\/www.adacyte.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adacyte.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.adacyte.com\/#organization","name":"Adacyte","url":"https:\/\/www.adacyte.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","contentUrl":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","width":165,"height":46,"caption":"Adacyte"},"image":{"@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific-corner\/6492","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific-corner"}],"about":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/types\/scientific-corner"}],"wp:attachment":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/media?parent=6492"}],"wp:term":[{"taxonomy":"scientific_tags","embeddable":true,"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific_tags?post=6492"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}